Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells.

BACKGROUND Diosmetin (DIOS) is the aglycone of the flavonoid glycoside, diosmin, derived naturally from the leaves of the legume, Olea europaea, and Acacia farnesiana. It has potent anticancer activity against multiple forms of cancers. However, the role of DIOS in renal carcinoma and its mechanism of action remain unclear. OBJECTIVE The purpose of this study is to investigate the effect of DIOS on cell viability and apoptosis in renal carcinoma cells and explore the possible mechanism of action. METHODS Cell viability, cytotoxicity, caspase activity, apoptosis, and expression of apoptotic related proteins were analyzed in renal carcinoma ACHN cells. RESULTS The results showed that DIOS inhibited the cell viability, and induced cytotoxicity and apoptosis in ACHN cells. Furthermore, DIOS increased expression of p53 mRNA and proteins, and downregulated phosphorylation of the phosphoinositide 3-kinase and protein B kinase (PI3K/AKT). In addition, it was observed that the anticancer effect of DIOS was significantly enhanced by the p53 activator, but inhibited by the p53 inhibitor. CONCLUSION Our data suggested that DIOS induced apoptosis in renal carcinoma ACHN cells by reducing AKT phosphorylation through p53 upregulation.

[1]  Sang-Youel Park,et al.  Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Qiang Zhou,et al.  Anti-Proliferation and Pro-Apoptotic Effects of Diosmetin via Modulating Cell Cycle Arrest and Mitochondria-Mediated Intrinsic Apoptotic Pathway in MDA-MB-231 Cells , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[3]  Luyong Zhang,et al.  Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non‐small cell lung cancer cells via Nrf2 inhibition , 2019, British journal of pharmacology.

[4]  Kohji Yamada,et al.  Mechanical insights into the regulation of programmed cell death by p53 via mitochondria. , 2019, Biochimica et biophysica acta. Molecular cell research.

[5]  M. Bulyk,et al.  The multiple mechanisms that regulate p53 activity and cell fate , 2019, Nature Reviews Molecular Cell Biology.

[6]  Xixi Lin,et al.  Diosmetin inhibits osteoclast formation and differentiation and prevents LPS‐induced osteolysis in mice , 2018, Journal of cellular physiology.

[7]  Xiaoping Zhou,et al.  Mutant p53 in cancer therapy—the barrier or the path , 2018, Journal of molecular cell biology.

[8]  G. Del Sal,et al.  Mutant p53 as a guardian of the cancer cell , 2018, Cell Death & Differentiation.

[9]  S. Shukla,et al.  Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest , 2018, International journal of oncology.

[10]  Yaping Liao,et al.  Cytoprotective effects of diosmetin against hydrogen peroxide-induced L02 cell oxidative damage via activation of the Nrf2-ARE signaling pathway. , 2018, Molecular medicine reports.

[11]  X. Ci,et al.  Diosmetin Alleviates Lipopolysaccharide-Induced Acute Lung Injury through Activating the Nrf2 Pathway and Inhibiting the NLRP3 Inflammasome , 2017, Biomolecules & therapeutics.

[12]  Kang Yang,et al.  Diosmetin protects against ischemia/reperfusion-induced acute kidney injury in mice. , 2017, The Journal of surgical research.

[13]  B. Liu,et al.  Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells. , 2017, Protein and peptide letters.

[14]  Xue Yang,et al.  Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway , 2017, PloS one.

[15]  Xiaohong Wang,et al.  Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signaling pathways. , 2016, Oncology letters.

[16]  B. Liu,et al.  Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP-2 and MMP-9 , 2016, Molecular medicine reports.

[17]  G. Mills,et al.  The PI3K/AKT Pathway and Renal Cell Carcinoma. , 2015, Journal of genetics and genomics = Yi chuan xue bao.

[18]  M. Bizzarri,et al.  Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review , 2013, Expert opinion on therapeutic targets.

[19]  N. Reiner,et al.  Synergistic effects of diosmetin with erythromycin against ABC transporter over-expressed methicillin-resistant Staphylococcus aureus (MRSA) RN4220/pUL5054 and inhibition of MRSA pyruvate kinase. , 2013, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[20]  R. Elble,et al.  Micromanagement of the mitochondrial apoptotic pathway by p53. , 2011, Frontiers in bioscience.

[21]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[22]  H. Miyake,et al.  p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. , 1998, International journal of oncology.

[23]  T. Fujioka,et al.  Infrequent Mutation of p53 Gene in Human Renal Cell Carcinoma Detected by Polymerase Chain Reaction Single‐strand Conformation Polymorphism Analysis , 1992, Japanese journal of cancer research : Gann.